Clinical Trial Update: Sacituzumab govitEcan in THYroid Cancers [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Sacituzumab Govitecan in differentiated thyroid cancer and anaplastic thyroid cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer
• Differentiated Thyroid Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Grupo Espanol de Tumores Neuroendocrinos | Conditions: Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer | Phase 2 | Status: RECRUITING